In a phase 1b, open-label, dose-escalation, multicentre study of patients with relapsed or refractory chronic lymphocytic leukaemia (CLL), the combination of the BCL-2 inhibitor, venetoclax (ABT-199/GDC-0199), and monoclonal anti-CD20 antibody, rituximab, showed a tolerable safety profile and induced deep and durable responses, with 41% of patients achieving complete response (CR).
Presented by Andrew Roberts, MB BS, PhD, FRCPA, FRACP, Royal Melbourne Hospital, Melbourne, Australia, at the 20th Congress of the European Hematology Association (EHA).
